• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Clinical Trial Activity in Russia Dipped in 2009

Clinical Trial Activity in Russia Dipped in 2009

March 5, 2010
CenterWatch Staff

According to Russia-based contract research organization (CRO) Synergy Research Group’s Annual Orange Report, Russia’s regulatory agency Federal Service on Surveillance in Healthcare and Social Development of the Russian Federation (RosZdravNadzor, RZN) approved 577 new clinical trials during 2009, 6% fewer than in 2008. Sixty percent, or 348 of the new studies, were multinational multi-center trials, down 4% from 2008.

Clinical trials in Russia in 2009 were sponsored by pharmaceutical companies from 28 countries. Most of them, 191, were initiated by Russian sponsors. U.S. sponsors initiated 128 trials followed by 51 trials by German sponsors, 42 by Swiss sponsors, 35 by UK sponsors, and 34 by Japanese sponsors.

Novartis sponsored the most new studies in Russia for one company, followed by Pfizer’s 22, Merck’s and GlaxoSmithKline’s 20 new trials each, and Boehringer Ingelheim’s 16 new trials.

In 2009, 85% of the new studies initiated in Russia fell into six major therapeutic areas. The greatest number of studies were initiated in the field of oncology, at 104 clinical trials. Sixty-six studies each were initiated in endocrine and metabolic diseases, and in respiratory diseases; 64 were initiated in cardiovascular; 40 in musculoskeletal and 38 in central nervous system.

Seven FDA inspections were conducted at Russian investigative sites during 2009, according to FDA data.

The full report will be presented by Synergy Research Group at the DIA EuroMeeting in Monaco during March 8-10, 2010, and will be available at Booth #5.

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing